K.V. Menshikov1,2, D.O. Lipatov2, A.V. Sultanbaev1, A.F. Nasretdinov1, Sh.I. Musin1, I.A. Menshikova2, N.I. Sultanbaeva1, R.R. Abdeev1, К.I. Murzakhanova2, A.D. Ibragimova3
1Republican Clinical Oncology Dispensary, Ufa
2Bashkir State Medical University, Ufa
3Institute of Clinical Medicine of the Samara State Medical University, Samara
Lipatov Danila O. ― student of the Faculty of Medicine at Bashkir State Medical University; Employee of the Republican Clinical Oncology Dispensary
3 Lenin Str., Ufa, 450008, Russian Federation, tel. +7-927-303-01-01, e-mail: lipatov911@gmail.com, ORCID ID: 0000-0002-3193-9008
Abstract. This study presents a retrospective analysis of the effectiveness of lenvatinib in patients with hepatocellular carcinoma (HCC) in the Republic of Bashkortostan. HCC is the most common malignant liver tumor, and its treatment poses significant challenges, particularly in advanced stages. Tyrosine kinase inhibitor therapy with lenvatinib has shown significant improvements in overall survival and progression-free survival rates. The study evaluates survival outcomes, the frequency of adverse effects, and the level of disease control after lenvatinib therapy. The results indicate that lenvatinib use in real clinical practice is both effective and well-tolerated, even in patients with advanced disease stages.
The objective of this study is to conduct a retrospective analysis of the efficacy of lenvatinib in patients with HCC.
Key words: hepatocellular carcinoma, liver cancer, lenvatinib, tyrosine kinase inhibitors, drug therapy.